Antibodies to acetylcholine receptor were found in 3 of 11 patients with a thymoma removed by operation but without myasthenia gravis. Because masthenia gravis may appear after removal of the thymoma, detection of antiacetylcholine receptor antibodies may have predictive value.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.30.2.201 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thymoma-Induced Severe Biventricular Failure without Myasthenia Gravis: Investigating Tachycardia-Induced Cardiomyopathy.
Am J Case Rep
March 2025
Department of Cardiology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
BACKGROUND Cardiomyopathy associated with thymoma is thought to be a cardiac manifestations of myasthenia gravis (MG). However, there are case reports of newly diagnosed thymoma presenting with cardiomyopathy without MG, and the mechanism remains unclear. The purpose of this report is to explore tachycardia-induced cardiomyopathy (TIC) as a potential mechanism for cardiomyopathy in thymoma without features of MG.
View Article and Find Full Text PDFDevelopment and Application of a Cell-Based Assay for Detecting Anti-Agrin Antibodies Associated With Myasthenia Gravis.
J Clin Neurol
March 2025
Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
Background And Purpose: Anti-agrin antibodies (agrin Abs) have recently been identified in patients with myasthenia gravis (MG), sometimes in conjunction with antibodies (Abs) to the acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), or low-density lipoprotein receptor-related protein 4. This study aimed to develop an in-house cell-based assay (CBA) for detecting agrin Abs, and to test its application to serum samples collected from individuals diagnosed with MG.
Methods: Agrin complementary DNA as cloned into a pCMV6-AC-GFP vector, which was subsequently transfected into human embryonic kidney 293T (HEK293T) cells.
A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder?
Cureus
February 2025
Neurology, University of Texas Medical Branch, Galveston, USA.
Myasthenia gravis (MG) is an autoimmune neuromuscular disease characterized by fatigable muscle weakness. While commonly linked to acetylcholine receptor (AChR) antibodies, other reported antibodies include muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), agrin, striated muscle, myosin, ryanodine receptor, and titin. Notably, titin antibodies are being highlighted for their role in MG pathogenesis, as they have been associated with increased disease severity.
View Article and Find Full Text PDFDouble-seropositive Myasthenia Gravis Following COVID-19: A case report.
Intern Med
March 2025
Department of Neurology, Hamamatsu Medical Center, Japan.
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness caused by antibodies targeting acetylcholine receptors (AChRs) or muscle-specific kinases (MuSK). Double-seropositive MG (DSP-MG) caused by both antibodies is rare. We herein report a 78-year-old woman who developed DSP-MG after COVID-19 infection.
View Article and Find Full Text PDFThe Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center.
J Clin Apher
April 2025
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies against proteins of the neuromuscular junction, such as the acetylcholine receptor (AChR). While therapeutic plasma exchange (TPE) has been a standard chronic therapy for patients with poorly controlled MG, new medications have recently been approved by the FDA for such patients. We report the impact of a new therapy, efgartigimod, on the number of therapeutic plasma exchanges performed on patients with generalized MG in our apheresis unit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!